The next R&D Paradigm Shift: PanOmics and iPSCs
Disease understanding & modelling, Impactful therapies, Commercial success
Welcome to Evotec’s 2nd Capital Market Day in 2023, taking place at our headquarters in Hamburg on 15 November from 8:30 to 16:00! We are looking forward to an exciting mix of poster sessions, presentations, and round table sessions with the focus on the two main topics PanOmics and iPSC-based cell therapy.
Please note: As an in-person-only event there is no possibility to join virtually, but we will provide a recording of the CEO’s speech after the event.
On the evening before our CMD, on 14 November, at 19:00 we are happy to invite you to a get-together with our Management at the Radisson Blu Hotel, Hamburg Airport. In the interest of a more efficient planning, it would be nice to hear from you whether you intend to join us. Please contact us under email@example.com.
08:00 AM - 09:00 AM
Registration & Poster Session
09:00 AM - 09:30 AM
Shaping (new) markets
09:30 AM - 10:45 AM
PanOmics – From patients for patients
10:45 AM - 11:00 AM
11:00 AM - 12:00 PM
12:00 PM - 01:30 PM
01:30 PM - 04:00 PM
Dr Werner Lanthaler (born in 1968, Austrian citizen) was appointed Chief Executive Officer of Evotec on 06 March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company.
He holds a doctorate in economics from Vienna University, earned his Master’s degree from Harvard University and holds a degree in Psychology. Further, Dr Werner Lanthaler serves in the Board of Directors of AC Immune SA (since July 2018).
Dr Cord Dohrmann (born in 1964, German citizen) joined Evotec as Chief Scientific Officer and Member of the Management Board in 2010. Dr Dohrmann has spent over 25 years in biomedical research at leading academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tübingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr Dohrmann completed his MA thesis at the Max Planck Institute in Tübingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996.
Dr Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining a Max Planck Institute spin-off company, DeveloGen, in 1999. During his ten-year tenure, he served the company in various management positions including CEO, leading DeveloGen from a start-up to an internationally recognised metabolic disease company. Dr Cord Dohrmann is a member of the Supervisory Boards of Eternygen and Breakpoint Therapeutics, a Non-Executive Member of the Board of Directors of Facio Therapies and a Board Observer of Immunitas Inc. He has been advising the European Commission, the Max Planck Institute as well as various venture capital firms. In February 2021, Dr Dohrmann was appointed to the German Council of Science and Humanities.
Dr Bhushan K. Bonde started in 2021 as Head of Innovation for In-silico R&D, Drug Discovery, at Evotec Pharma, Abingdon, UK. Since May 2022 he is also Visiting Professor of Computational Biology at the Digital Futures Institute of the University of Suffolk.
Previously, from 2014 to 2021 he held various positions at UCB-Celltech, UK, most recently as Data Integration Head. His further professional stations, also in the UK, were at GSK as Investigator in Computional Biology (2009-2014).
He holds a Master of Science in Bioprocess Technology (Engineering) from the Institute of Chemical Technology (UICT), University of Mumbai, India and a Bachelor of Pharmacy of the Mahatma Gandhi Vidyamandir’s Pharmacy College, University of Pune, India.
He received his doctorate as Ph.D. in Computional Biology of the School of Biological & Molecular Science, Oxford Brookes University, Oxford, UK.
Dr Christiane Honisch (born in 1968, German and US citizen) joined Evotec as the Head of Diagnostics in January 2021. From 2018-2020 she was Head of Global Business Intelligence at Eppendorf GmbH.
Dr Christiane Honisch built the first half of her career in California, USA where she led Illumina’s Microbiology business as Director of Microbiology Markets from 2015-2018 and established key partnerships with Biomérieux as well as the University of San Diego California Center of Microbiome Innovation. She joined Illumina from Roche Molecular Diagnostics in Pleasanton, California, where she was Director of Infectious Disease Research from 2013-2015 responsible for in vitro diagnostics (IVD) research and microbial surveillance. Her team receive the Roche Innovation Award in 2014. Previously, she established a Genomics Core Facility at the University San Diego California in 2012 and was a key individual in developing the commercial use of mass spectrometry for diagnostic applications in microbioloy and ultrasensitive detection of cancer at Sequenom, Inc. in San Diego, CA from 2000-2011. The global microbial monitoring system developed under her leadership was installed at the CDC in Atlanta and the Health Protection Agency in London, UK.
She holds a doctorate in molecular biology and microbiology from the University Carolo-Wilhelmina zu Braunschweig, Germany. Further, Dr Christiane Honisch serves on the Boards of IMIDomics Inc. (since 2022), PathoQuest Inc. (2018-2023) and is a member of the Innovation Advisory Committee at Deutsches Elektronen-Synchrotron in Hamburg.
Olivier Radresa joined Evotec in 2019 as Senior Vice President in Kidney Therapeutics. In his former position he was Head of Drug Discovery at EPICS Therapeutics from 2017 until 2019. In 2017 he worked as Manager Metabolic Disorders & Complications at the McGill University Health Center in Montreal, Canada. Before, he gained more than 10 years of as Senior Research Scientist Kidney and Respiratory Diseases at Vertex Pharmaceuticals (2015-2017) in Montreal, as Research Associate GPCRs in Renin-Angiotensin System at McGill University Montreal (2014-2015) as Founder at O.R.B.I.T. Bioassays Integration & Technologies (2012-2014) also in Montreal, and as Research Scientist II CNS & Pain iMed at Astra Zeneca, Montreal (2006-2012). He started his career as Post-Doc Scientist Pain & Alzheimer at Johnson & Johnson in Beerse, Belgium (2003-2006) after having graduated as PhD in Bioengineering (2001) at the Université Libre de Bruxelles followed by two years as Research Associate there (2001-2002). Olivier is the author of several scientific publications.
Sandra Lubitz is heading the iPSC platform for drug discovery (E.iPSC) at our headquarters in Hamburg, Germany. Together with her team she strives to provide human iPSC-derived disease models for drug screening as a novel approach for the discovery of therapeutics that can radically improve patients' lives. With more than 20 years of research experience in stem cells, Sandra is highly regarded as an expert in this field. Indeed, stem cells run like a common thread through all of Sandra’s career milestones. Ever since her PhD, which she obtained from the International Max Planck Research School in Dresden, Germany in the lab of Prof. Francis Stewart, Sandra was intrigued by the potential of human stem cell models. Upon transition to industry, she started working for Genea Biocells, a stem cell company based in Sydney, Australia and subsequently Pfizer Regenerative Medicine / Neusentis in Cambridge, UK. Upon joining Evotec in 2011, Sandra has played a key role in establishing Evotec’s iPSC platform and is working closely with our management team on corporate development activities for iPSC, including new partnerships.
Dr Andreas Scheel was appointed EVP Head of Cell Therapy in 2019. He has spent > 20 years in the Biotech industry and was one of the early employees at Evotec when he joined 1997. Over the years he held different senior leadership positions within Evotec and made significant contributions to the company strategy and growth. Between 2009 and 2012 he served as Head of In vitro Biology at OSI Prosidion in Oxford, UK. He also recently served as Board member for PanCELLa Inc. (2020-2022).
Andreas holds a PhD in Cell Biology from the University of Cambridge, UK and got his Master’s Degree at the University of Tuebingen.
Christine Guenther joined Evotec in Feb 2021 as Entrepreneur in Residence and Medical Director Cell Therapy. As part of the leadership team Christine brings more than 30yrs expertise in cell therapy. From 2008 to 2020 she served as CEO and Medical Director at Apceth, Cell & Gene therapy (Munich, GER, now Minaris) building the Biotech from start-up to a profitable CDMO and research company. The company developed the worldwide first clinical study with genetically modified stem cells (MSC). Apceth was acquired by Hitachi Chemical in 2019 and integrated into a global CDMO network. Prior to that she was Medical Director and Qualified Person at a non-profit foundation for stem cell donation. From 1988 – 2002 she was working as Physician, specializing in Hematology & Oncology, with focus on stem cell tlx at the University Hospital Munich and as Senior Resident (Oberarzt) at an Academic Hospital.
She holds a medical degree and specialization in Hematology/ Oncology from University of Munich and did her doctorate in experimental Hematology at the Helmholtz Society (Munich). She worked > 10 yrs as certified Qualified Person and is Manager of Regulatory Affairs.
Since 2020 Markus Dangl serves as Executive Vice President at Evotec, leading the internal Oncology and I&I RnD organization and portfolio. He joined Evotec from Achilles Therapeutics, were he was as CSO responsible for the development and clinical translation of TIL-based cancer therapies. Prior to that, he held the position as as Senior Vice President for Research and Development at Medigene AG, working on autologous T cell product candidates. Markus spent 15 years at Roche in Germany, Singapore and the US, holding various managerial positions and was involved in the design, execution and clinical transition of multiple oncology projects. He holds a PhD in Biochemistry from the University of Innsbruck in Austria